Author/Editor		Kopač, Maruša; Rijavec, Matija; Korošec, Peter; Bidovec, Urška; Kern, Izidor; Vantur, Romana; Škrgat, Sabina
Title		Heterogeneous response of airway eosinophilia to anti-IL-5 biologics in severe asthma patients
Type		članek
Vol. and No.		Letnik 12, št. 1
Publication year		2022
Volume		str. 1-12
ISSN		2075-4426 - Journal of personalized medicine
Language		eng
Abstract		Many questions concerning responders (R) and nonresponders (NR) in severe eosinophilic asthma (SEA) after blocking the IL-5 (interleukin 5) pathway are still not clear, especially regarding the early parameters of response to biologics in personalized treatment strategies. We evaluated 17 SEA patients treated with anti-IL-5 biologics (16 patients mepolizumab, one patient benralizumab) before the introduction of biologics, and at a week 16 follow-up. Clinical, cellular and immunological parameters in peripheral blood were measured in R and NR. Sputum induction with the measurement of cellular and immunological parameters was performed at 16 weeks only. There were 12 R and 5 NR to biologics. After 16 weeks, there was a significant improvement in percentages of FEV1 (p = 0.001), and asthma control test (ACT) (p = 0.001) in the R group, but not in NR. After 16 weeks, the eosinophils in induced sputum were 27.0% in NR and 4.5% in R (p = 0.05), with no difference in IL-5 concentrations (p = 0.743). Peripheral eosinophilia decreased significantly in NR (p = 0.032) and R (p = 0.002). In patients with SEA on anti-IL-5 therapy, there was a marked difference in airway eosinophilic inflammation between R and NR already at 16 weeks, after anti-IL-5 introduction.
Keywords		težka astma anti-IL-5 biološka zdravila eozinofilija dihalne poti sputum